Search Results for "Alzheimers Disease Update"

03:11 EST 27th November 2014 | BioPortfolio

Matching Channels

Vascular Dementia

Vascular Dementia accounts for 25% of all dementias (the second most commen cause after Alzheimers. It is the cumulative effects of many small strokes - patients often have evidence of vascular path...

Huntington's Disease

Huntington's disease is a hereditary disease caused by a defect in a single gene on Chromosome 4 that is inherited in an autosomal dominant fashion. The defect causes a part of DNA, called a CAG...

Eye disease

Gaucher's disease

Gaucher's (go-SHAYZ) disease occurs when certain harmful fatty substances accumulate to excessive levels in your liver, spleen, lungs, bone marrow and, less commonly, brain. This accumulation of...

Chikungunya disease

Matching News

Funding Speeds Identification of Drugs For Alzheimers Prevention

The National Institutes of Health (NIH) has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer’s disease in people destined to get the debi...

Funding Speeds Drugs Identification For Alzheimers Prevention

The National Institutes of Health (NIH) has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer’s disease in people destined to get the debi...

Why Do So Many Women Get Alzheimers? New Research Points to Genetics, Other Factors

(Washington Post) – Of the more than 5 million people in the United States who have been diagnosed with Alzheimer’s, the leading cause of dementia, two-thirds are women. Because advancing age...

FDA Approves NeuroGenetic Pharmaceuticals, Inc. Application To Begin Clinical Trials For Its NGP 555 Compound To Treat And Prevent Alzheimer???s Disease

SAN DIEGO--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application from NeuroGenetic Pharmaceuticals, Inc. (NGP) to begin clinical tria...

Neurotrope To Host Conference Call

PLANTATION, Fla., Aug. 20, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that it will host a conference call to provide an update on Company activities. Access information: ...

Coronary artery disease: Detection of ischaemic heart disease in symptomatic women

The 2014 revision of the 2005 AHA consensus statement on the evaluation of women with suspected ischaemic heart disease is a major update. The authors discuss the spectrum of ischaemic heart disease a...

Researchers discover a “switch” in Alzheimer’s and stroke patient brains

A switch in the brain of Alzheimers and stroke patients prevents formation of new neurons.=

Lyme Disease Activists Protest at IDWeek

Lyme disease advocates registered as attendees at the infectious diseases conference are calling for physicians to update their guidelines. Medscape Medical News

Matching PubMed Articles

Melatonin and abeta, macular degeneration and alzheimers disease: same disease, different outcomes?

Aging is the common denominator and the highest risk factor for macular degeneration and Alzheimers Disease (AD). Important pathological hallmarks common to both diseases are the presence of amyloid ...

Self management for patients with chronic obstructive pulmonary disease.

Self management interventions help patients with chronic obstructive pulmonary disease (COPD) acquire and practise the skills they need to carry out disease-specific medical regimens, guide changes in...

UCH-L1 C-terminus plays a key role in protein stability but its farnesylation is not required for membrane association in primary neurons.

Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) is a deubiquitinating enzyme (DUB) that is highly expressed in neurons. A possible role for UCH-L1 in neurodegeneration has been highlighted because of its p...

Update on obstructive sleep apnea and its relation to COPD.

Chronic obstructive pulmonary disease (COPD) is a common and preventable lung disease that affects millions of people in the United States. Sleep disorders including obstructive sleep apnea (OSA) are ...

Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

McArdle disease (Glycogen Storage Disease type V) is caused by an absence of muscle phosphorylase leading to exercise intolerance, myoglobinuria rhabdomyolysis and acute renal failure. This is an upda...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement